Who
Uma Sinha
Director
Company insider
Files Form 4 as: Director, ProKidney; Chief Scientific Officer, Eidos Therapeutics; Chief Scientific Officer, BridgeBio Pharma.
In numbers
- Trades disclosed
- 53
- Buys
- 1
- Sells
- 9
- Bought
- $238K
- Sold
- $3.5M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 5 Nov 2018
- Last trade
- 28 May 2026
- Last filed
- 29 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 28 May 2026filed 29 May 2026 | PROK ProKidneyoption or derivative · Biotechnology | SEC FORM 4 Code A | —135,000 at $0.00 | filing |
| 28 May 2026filed 29 May 2026 | PROK ProKidneyoption or derivative · Biotechnology | SEC FORM 4 Code A | —135,000 at $0.00 | filing |
| 29 May 2025filed 2 Jun 2025 | PROK ProKidneyoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,862 at $0.00 | filing |
| 30 May 2024filed 3 Jun 2024 | PROK ProKidneyoption or derivative · Biotechnology | SEC FORM 4 Code A | —62,558 at $0.00 | filing |
| 29 Jun 2023filed 3 Jul 2023 | PROK ProKidneyoption or derivative · Biotechnology | SEC FORM 4 Code A | —48,128 at $0.00 | filing |
| 11 Jul 2022filed 13 Jul 2022 | PROK ProKidneyBiotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 26 Jan 2021filed 28 Jan 2021 | Eidos Therapeutics | SEC FORM 4 Code U | —303,525 | filing |
| 26 Jan 2021filed 28 Jan 2021 | Eidos Therapeuticsoption or derivative | SEC FORM 4 Code D | —60,000 | filing |
| 13 Jan 2021filed 15 Jan 2021 | Eidos Therapeutics | SEC FORM 4 Sold | $84K696 at $121.11 | filing |
| 13 Jan 2021filed 15 Jan 2021 | Eidos Therapeutics | SEC FORM 4 Sold | $70K572 at $122.27 | filing |
| 13 Jan 2021filed 15 Jan 2021 | Eidos Therapeutics | SEC FORM 4 Sold | $185K1,498 at $123.48 | filing |
| 13 Jan 2021filed 15 Jan 2021 | Eidos Therapeutics | SEC FORM 4 Sold | $615K4,934 at $124.72 | filing |
| 13 Jan 2021filed 15 Jan 2021 | Eidos Therapeutics | SEC FORM 4 Sold | $251K2,000 at $125.35 | filing |
| 13 Jan 2021filed 15 Jan 2021 | Eidos Therapeutics | SEC FORM 4 Sold | $38K300 at $126.39 | filing |
| 15 Dec 2020filed 17 Dec 2020 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,912 at $0.00 | filing |
| 15 Dec 2020filed 17 Dec 2020 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,832 at $0.00 | filing |
| 15 Dec 2020filed 17 Dec 2020 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,717 at $0.00 | filing |
| 2 Dec 2020filed 4 Dec 2020 | Eidos Therapeutics | SEC FORM 4 Sold | $340K3,798 at $89.63 | filing |
| 2 Dec 2020filed 4 Dec 2020 | Eidos Therapeutics | SEC FORM 4 Sold | $64K702 at $90.63 | filing |
| 2 Dec 2020filed 4 Dec 2020 | Eidos Therapeutics | SEC FORM 4 Sold | $28K300 at $91.89 | filing |
News
BridgeBio Pharma (NASDAQ:BBIO) Given New $91.00 Price Target at CitigroupBBIO · dailypolitical.com · 19 Oct 2026
0 headlines in the last 90 days name Uma Sinha; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.